Dapagliflozin - Not Just for Diabetes Anymore?
The DAPA-HF trial evaluated patients with heart failure with reduced ejection fraction (HFrEF), both with and without type 2 diabetes, treated with dapagliflozin compared with placebo. The results of the trial were published in the New England Journal of Medicine in September 2019.
Among patients with symptomatic HFrEF, dapagliflozin was beneficial. Dapagliflozin vs. placebo was associated with a reduction in cardiovascular deaths and heart failure events. Dapagliflozin was also associated with improvement in symptoms. Benefit was consistent across the age spectrum, in diabetics/nondiabetics, and across the range of baseline health status. There was no sign of adverse safety events. Dapagliflozin may signal a new approach in the treatment of patients with HFrEF.
Due to the results of the DAPA-HF trial, on October 21, 2019, the FDA added an indication for dapagliflozin to “reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors.”